Surrozen, Inc. (SRZN)
- Previous Close
8.61 - Open
8.14 - Bid --
- Ask --
- Day's Range
8.14 - 8.98 - 52 Week Range
4.50 - 16.19 - Volume
11,124 - Avg. Volume
16,966 - Market Cap (intraday)
28.725M - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
-- - EPS (TTM)
-21.33 - Earnings Date Apr 29, 2024 - May 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
33.00
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
www.surrozen.comRecent News: SRZN
Performance Overview: SRZN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SRZN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SRZN
Valuation Measures
Market Cap
28.72M
Enterprise Value
-3.94M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.76
Enterprise Value/Revenue
-0.12
Enterprise Value/EBITDA
0.10
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.69%
Return on Equity (ttm)
-75.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-43.04M
Diluted EPS (ttm)
-21.33
Balance Sheet and Cash Flow
Total Cash (mrq)
36.04M
Total Debt/Equity (mrq)
8.91%
Levered Free Cash Flow (ttm)
-23.48M